Basecare Ranked Among the TOP10 of Assisted Reproduction Enterprises According to “2021 Forbes China Maternity and Childhood Industry List”.
Recently, “2021 Forbes China Maternity and Childhood Industry List” was released and Basecare was ranked among the top 10 of assisted reproduction enterprises. The list was targeted at maternity and childhood industry and lasted for 4 months, which aimed at selecting the leading enterprises with management and innovation in sub-industries. Each sub-industry had hundreds of evaluation indicators to ensure the professionalism and impartiality.
Three features of Basecare:
01: Leading innovations and R&D.As a leader in assisted reproduction, Basecare will continue to take the road of innovative development and complete the registration and certification of the full reproductive cycle product line in five years. PGS kit (PGT-A) developed by Basecare is the first PGT product approved by NMPA for marketing. It is estimated that PGT-M and PGT-SR kit will be approved for registration in 2022 and 2024 respectively.
Meanwhile, Basecare provides an integrated experimental platform solution from testing reagents to embryo storage and realized the automatic and domestic hardware upgrading in assisted reproduction, and built a R&D and manufacturing center of high-end reproductive equipment. We are developing a variety of intelligent instruments. It is estimated that the registration of NGS sequencer (DA500) and cryostorage system (BSG800A) will be approved in 2022 and 2023 respectively. We will complete the registration and certification of products in the full reproductive cycle in the next five years.
02：Golden racetracks with promising future.
With the implementation of the "three-child policy", Basecare has a great opportunity for development in reproductive health. However, couples with economic strength and willingness to have two or more children often miss the golden period of childbearing, and their fertility is inferior to that of young couples, so they need assisted reproduction services even more. Improving the success rate of birth and birth quality is also the focus of this group, which can be realized by genetic testing of assisted reproduction. Therefore, the testing of assisted reproductive genes, which can improve fertility quality, is expected to become one of the most promising racetracks in the assisted reproductive industry chain. According to a report by Frost & Sullivan, the market of medical devices in reproductive genetics in China is expected to reach CNY11.2 billion in 2024, and the market of the third-generation IVF is expected to reach CNY25 billion in 2024.
03：Elite team starts the era of eugenics.
As the first listed company in the reproductive genetics industry in China, since the listing on February 8, 2021, Basecare has set up a golden combination featuring "one body and two wings" with the marketing team led by senior sales director Wang Hui as the main body, the marketing team led by overseas returnee Dr. Xu Hao and the clinical team led by genetic expert Hu Taotao as the auxiliary, and fully promoted the popularization and application of PGT (Preimplantation Genetic Testing) technology in clinic. In the future, Basecare will accelerate the industrialization layout and attract more talents around the world to build a world-class marketing team of over 200 people based on “one body and two wings” structure in order to serve the clinic and accelerate the development of assisted reproduction market in China. Meanwhile, in terms of talent team building, Basecare plans to introduce several academician teams and establish a global top KOL scientific advisory team.
With favorable policies and market promotion, reproductive health ushers in great opportunities for development. In the future, Basecare will continue to promote the development of gene technology in reproductive health and emphasize technological breakthroughs and innovations in disruptive technologies. Basecare aims to contribute to national eugenics through technological innovations by helping infertile patients to have children, ensure patients carrying genetic disease genes have healthier children, and eliminate problems of fertility in China.